Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Policy Sets Boundaries On Transcatheter Valve Procedure

Final Coverage Plan Includes Compromise, But Maintains Evidence Development, Other Restrictions

This article was originally published in The Gray Sheet

Executive Summary

New Medicare coverage policy for transcatheter aortic valve replacement is a significant step for the nascent procedure and a possible window into how the agency will address future high-profile, early-stage technologies.

You may also be interested in...



CMS Proposes More Flexible Requirements For Centers Performing TAVR

A proposed update to the 2012 National Coverage Policy for transcatheter aortic valve replacement (TAVR) would make it easier for hospitals to begin a TAVR program while slightly raising the procedure-volume requirements for maintaining a continuing TAVR program. The agency believes the new rules would balance the need to expand patient access to TAVR while ensuring the quality and safety of TAVR procedures covered by Medicare.

National Medicare Analysis Opened For Watchman Device

CMS will consider a national policy for the left atrial appendage closure device in response to a request from Boston Scientific.

Medicare 'Coverage With Evidence' May Rise With FDA Postmarket Emphasis

As FDA touts plans to shift clinical data requirements when possible to the postmarket phase, a top CMS official highlights the importance of the Medicare coverage with evidence development policy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel